Equities Analysts Set Expectations for DNLI FY2027 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at Zacks Research issued their FY2027 earnings per share estimates for shares of Denali Therapeutics in a research report issued on Thursday, March 13th. Zacks Research analyst A. Chakraborty expects that the company will post earnings per share of ($2.25) for the year. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08.

A number of other research analysts have also issued reports on the company. B. Riley restated a “buy” rating and set a $35.00 price objective (down previously from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Oppenheimer reduced their price target on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research report on Monday, March 3rd. Morgan Stanley initiated coverage on Denali Therapeutics in a research report on Friday, March 7th. They set an “overweight” rating and a $33.00 price target for the company. Deutsche Bank Aktiengesellschaft initiated coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $31.00 price target for the company. Finally, Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.20.

Denali Therapeutics Price Performance

NASDAQ:DNLI opened at $14.51 on Monday. Denali Therapeutics has a 12-month low of $14.01 and a 12-month high of $33.33. The firm has a market capitalization of $2.11 billion, a P/E ratio of -5.26 and a beta of 1.46. The business has a 50 day simple moving average of $20.04 and a 200 day simple moving average of $23.83.

Insider Transactions at Denali Therapeutics

In other news, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the sale, the director now directly owns 107,976 shares of the company’s stock, valued at $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steve E. Krognes sold 3,339 shares of the business’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the sale, the director now directly owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock valued at $973,442 over the last three months. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of DNLI. Victory Capital Management Inc. raised its position in Denali Therapeutics by 163.7% during the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock valued at $1,162,000 after buying an additional 24,767 shares during the period. FMR LLC raised its position in Denali Therapeutics by 3,234.3% during the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after buying an additional 7,596,508 shares during the period. Algert Global LLC raised its position in Denali Therapeutics by 82.4% during the third quarter. Algert Global LLC now owns 48,630 shares of the company’s stock valued at $1,417,000 after buying an additional 21,975 shares during the period. Proficio Capital Partners LLC acquired a new position in Denali Therapeutics during the fourth quarter valued at $514,000. Finally, JPMorgan Chase & Co. raised its position in Denali Therapeutics by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock valued at $6,857,000 after buying an additional 14,324 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.